Navigation Links
For the First Time, a Glioma ¨C Brain Cancer ¨C may be Eliminated by a Chinese Research/Medical Team, Using a Novel Stem Cell Based Therapy of Cellonis Biotech, Beijing
Date:12/17/2009

BEIJING, Dec. 17 /PRNewswire-Asia/ -- Using a novel stem cell based technology of Cellonis Biotechnologies, Beijing, a Chinese research/medical team may eliminate a glioma -- brain cancer -- of a 36 year old Norwegian patient in a hospital in Beijing. The treatment shows that the activated immune system can directly kill tumor stem cells as well as cancer daughter cells. The amazing outcome of this novel treatment within a Comprehensive Cancer Therapy tells Cellonis that the future vaccination therapies may be targeted towards cancer stem cell lysates to improve the antigen-presenting Dendritic Cell response.

(Photo: http://www.newscom.com/cgi-bin/prnh/20091217/CNTH007)

Arve Johnsen, 36, from Norway, a patient diagnosed with glioma in 2006 and relapsed in 2009 after surgical resection. He arrived in Beijing in August 2009 with his wife Vanja and a one-year-old daughter, with the hope that the doctors in Norway were wrong. They told the family there is no other option anymore in the Scandinavian countries or in Europe for Arve to control the progress of disease and prolong his life. Driven by the hope that their daughter could grow up with a father, the Johnsen family started a research campaign to find other treatments worldwide, to give Arve a new hope.

Comprehensive Cancer Therapy in China

The Johnsen's, having heard about the sustainable success of a Comprehensive Cancer Therapy (CCT) in China, decided to try for this last chance in a country 10,000 km away from Norway. This kind of CCT had been developed in the past few years by a Chinese team of scientific researchers and clinical doctors in Beijing, combining conventional canc
'/>"/>

SOURCE Cellonis Biotechnologies
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Ind. , May 23, 2013  Rahal Letterman ... in human cord blood stem cell banking and therapeutics, ... of the No. 16 Acorn Stairlifts Indy car driven ... for the remainder of the IZOD IndyCar 2013 season. ... (RLL) will work to support awareness of umbilical cord ...
(Date:5/23/2013)... Auburn, MA (PRWEB) May 23, 2013 ... one inch wide and provide 15 mm travel ... nanometers. The small dimensions make these new ... in confined spaces. A vacuum rated version is ... Datasheet:, Drawings, specifications and datasheets can be found ...
(Date:5/23/2013)... HILLS, Calif. , May 23, 2013  Saddleback ... recently became the first hospital on the ... robotic technology. This new surgical option provides women with ... Marc Winter , M.D., ... gynecologist and surgeon and medical director of minimally invasive ...
(Date:5/23/2013)... BioTrends Research Group, one of the ... biopharmaceutical issues, finds that, unaided, one in five ... that in the past six months, they have ... anticipation of the next generation of HCV treatments—notably ... 6 percent reported that they had begun warehousing ...
Breaking Biology Technology:StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3Precision Positioning System Uses Miniaturezed Piezo Linear Motor: LPS-24 Linear Stage by PI 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 2Saddleback Memorial Surgeon First on the West Coast to Perform Single-Site Robotic Hysterectomy 3The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3
... OSLO, Norway, June 17 , ... Shown to Improve Remission Rates and,Reduce Short-Term Mortality Compared ... Pharma ASA (OSE: CLAVIS) today announces positive final results,from ... drug, elacytarabine,(CP-4055), in patients with late-stage acute myeloid leukaemia ...
... ... and Communications Convergence , ... San Diego, CA (PRWEB) June 17, 2009 -- CommNexus and Leap ... unlimited wireless services, today announce their support for EvoNexus, a non-profit incubator dedicated to ...
... by Advanced Cell Technology,s Chief Scientist, Robert Lanza yields answers ... 16 MSNBC.com featured today Dr. Robert Lanza,s book (co-authored ... Consciousness are the Keys to Understanding the True Nature of ... Log." The article by Science Editor Alan Boyle includes ...
Cached Biology Technology:Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 2Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 3Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 4Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 5Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 6Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia 7San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 2San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 3San Diego Wireless Heavyweight Leap Wireless Supports New Start-up Incubator 4MSNBC Publishes Free Online Abridgment of 'Biocentrism' 2MSNBC Publishes Free Online Abridgment of 'Biocentrism' 3
(Date:5/22/2013)... also conclude that the 20 percent reduction in ... versus chest X-ray (CXR) screening previously reported in ... screening centers in the United States. , Philadelphia, ... patients about the benefits and risks of LDCT ... New England Journal of Medicine of ...
(Date:5/22/2013)... major new effort to educate the public and decision ... clean water that looms ahead in the 21st century. ... current edition of Chemical & Engineering News , ... the world,s largest scientific society. , Bassam Z. Shakhashiri, ... Ph.D., explain that shortages of reliable supplies of fresh ...
(Date:5/22/2013)... health effects from disposal of millions of rechargeable ... recommend stronger government policies to encourage recovery, recycling ... the conclusion of a new paper in the ... , Oladele A. Ogunseitan and colleagues point out ... everything from smart phones to components in new ...
Breaking Biology News(10 mins):NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... Launches New Multi-Modal Biometric Identification Solution ... Enhanced Performance and Interoperability, SCHAUMBURG, Ill., March ... announced that it has been selected by the ... Biometric Identification,Solution (BIS). Motorola,s latest BIS solution features ...
... a genetic variant that can protect them after heart ... at Washington University School of Medicine in St. Louis ... effect that resembles that of beta blockers, drugs widely ... reason why beta blockers don,t appear to benefit some ...
... Researchers from The University of Arizona and Columbia University ... together and pull with forces far stronger than experts ... including Magdalene Maggie So, a member of the BIO5 ... College of Medicine, studied Type IV pili or ...
Cached Biology News:Motorola Biometric Identification System Selected by West Virginia State Police 2Many African-Americans have a gene that prolongs life after heart failure 2Many African-Americans have a gene that prolongs life after heart failure 3Many African-Americans have a gene that prolongs life after heart failure 4University of Arizona scientist shares in discovery of microbe filaments' power 2
Ideal for chemical processing that requires downward flow of exhaust fumes. Powderful 1200 CFM blower draws fumes into sub-surface bonded charcoal filter for safe removal of organic vapors (final HEP...
... mass numbers as a trigger, precisely isolates ... investigation and research of natural compounds. Key ... preparative operation. Switching between modes is simple ... support provides a quick solution for chemists ...
... Label IT siRNA Tracker Intracellular Localization Kit ... label and deliver siRNA, of your design, ... in vitro tracking experiments. Subcellular localization and ... be monitored following introduction of the labeled ...
Selective media for Salmonella...
Biology Products: